Brentuximab Vedotin (SGN-35) as Salvage Therapy for Males With Advanced and Platinum-resistant Germ-cell Tumors. An Open Label, Single Group, Phase 2 Trial
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2016
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Germ cell and embryonal neoplasms
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 07 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Jan 2014 Status changed from not yet recruiting to recruiting; according to ClinicalTrials.gov record.